TITLE

Inhaled corticosteroids may carry less risk of BMD reduction in postmenopausal women

PUB. DATE
April 2003
SOURCE
Formulary;Apr2003, Vol. 38 Issue 4, p193
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Discusses the results of a study showing that moderate doses of inhaled corticosteroids carry less risk than traditional oral corticosteroid therapy with respect to reduction of bone mineral density (BMD) in post-menopausal women. Overview of the study; Effect of oral glucocorticoid treatment on BMD of trabecular bone.
ACCESSION #
9533173

 

Related Articles

  • Clinical osteoporosis probability scoring system: Selection of menopausal women for bone densitometry screening. Arab, Maliheh; Hojatoleslami, Simin; Jamshidi, Leila; Yaseri, Mehdi; Yaraghi, Mansoureh; Sheibani, Kourosh // Pakistan Journal of Medical Sciences;Jan2012, Vol. 28 Issue 1, p97 

    Objectives: To formulate a clinical scoring system for evaluating people at risk of osteoporosis before ordering Bone Mass Densitometry. Methodology: Eighty two probable clinical osteoporosis related factors were checked in 325 females referred for Bone Mass Densitometry testing in Hamadan...

  • Asthma, Inhalers, and Your Bones.  // Running & FitNews;Jul/Aug2002, Vol. 20 Issue 7, p1 

    Provides information on the effect of inhaled corticosteroids for asthma on bone density.

  • Oral corticosteroids decrease bone density in older women.  // Modern Medicine;May96, Vol. 64 Issue 5, p57 

    Presents an abstract of the article `Inhaled and oral corticosteroids: Their effects on bone mineral density in older adults,' by J.F. Marystone, E.L. Barrett-Connor and D.J. Morton, published in the `American Journal of Public Health' in December 1995.

  • Relationship Between Systemic Corticosteroids and Osteonecrosis. Gebhard, K.L.; Maibach, H.I. // American Journal of Clinical Dermatology;Nov/Dec2001, Vol. 2 Issue 6, p377 

    Numerous reports describe osteonecrosis after oral corticosteroid therapy. It is still uncertain if corticosteroid treatment alone or in combination with other factors leads to the development of this condition. The literature presents controversial clinical and experimental data. The most...

  • Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus. Mendoza-Pinto, Claudia; García-Carrasco, Mario; Sandoval-Cruz, Hilda; Escárcega, Ricardo O.; Jiménez-Hernández, Mario; Etchegaray-Morales, Ivet; Soto-Vega, Elena; Muñoz-Guarneros, Margarita; López-Colombo, Aurelio; Delezé-Hinojosa, Margarita; Cervera, Ricard // Clinical Rheumatology;Jan2009, Vol. 28 Issue 1, p65 

    The aim of this study was to determine the prevalence and risk factors for low bone mineral density (BMD) in women with systemic lupus erythematosus (SLE). A cross-sectional study was conducted among 100 pre-menopausal patients with SLE. Patients were evaluated using a questionnaire about the...

  • Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid Therapy. Wallach, S.; Cohen, S.; Reid, D. M.; Hughes, R. A.; Hosking, D. J.; Laan, R. F.; Doherty, S. M.; Maricic, M.; Rosen, C.; Brown, J.; Barton, I.; Chines, A. A. // Calcified Tissue International;Oct2000, Vol. 67 Issue 4, p277 

    Men and women (n = 518) receiving moderate-to-high doses of corticosteroids were enrolled in two studies with similar protocols and randomly assigned to receive either placebo or risedronate (2.5 or 5 mg) for 1 year. All patients received daily calcium supplementation (500–1000 mg), and...

  • Dietary calcium and bone mineral density in premenopausal women with systemic lupus erythematosus. Chong, H. C.; Chee, S. S.; Goh, E. M. L.; Chow, S. K.; Yeap, S. S. // Clinical Rheumatology;Feb2007, Vol. 26 Issue 2, p182 

    The primary objective of this study was to determine the relationship between dietary calcium intake and bone mineral density (BMD) in premenopausal women with systemic lupus erythematosus (SLE) on corticosteroids (CS). The secondary aim was to identify other risk factors for osteoporosis in...

  • Osteoporosis in mixed connective tissue disease. Bodolay, E.; Bettembuk, P.; Balogh, Á.; Szekanecz, Z. // Clinical Rheumatology;Sep2003, Vol. 22 Issue 3, p213 

    The existence of osteoporosis in 58 postmenopausal women with mixed connective tissue disease (MCTD) was investigated. The mean bone mineral density assessed by dual energy X-ray absorptiometry in the lumbar spine was decreased in 25.8% of the patients, reflecting osteoporosis (T score < -2.5)....

  • Alendronate.  // AHFS Consumer Medication Information;Apr2018, p1 

    Alendronate is used to treat and prevent osteoporosis (a condition in which the bones become thin and weak and break easily) in women who have undergone menopause (''change of life,'' end of menstrual periods) and to treat osteoporosis in men. Alendronate is also used to treat osteoporosis in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics